Areteia Therapeutics
CompanyUnited States
Areteia Therapeutics develops one asset, in phase 2 (dexpramipexole in chronic obstructive pulmonary disease). Mostly small molecule; based in the United States.
- 1
- Asset
- Furthest stage
- Phase 2
- Raised
- $425M
- 1
- Trial
- 0
- Signals
Pipeline
1Reduces blood absolute eosinophil counts
Phase 2, Small molecule, chronic obstructive pulmonary disease
Full company profiles: pipeline, trials, funding and people.
In the full profile
- Evidence behind the mechanisms1
- Trials1
- Funding rounds and grants2
- People11
- Similar companies6